# Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc

> **NCT06084338** · PHASE2 · RECRUITING · sponsor: **VA Office of Research and Development** · enrollment: 60 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **RADIATION:** stereotactic ablative radiotherapy
- **DRUG:** Pluvicto
- **DRUG:** topical testosterone

## Key facts

- **NCT ID:** NCT06084338
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-14
- **Primary completion:** 2027-11-29
- **Final completion:** 2028-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06084338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06084338, "Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06084338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*